Aikenuo Completes Series A+ Financing, Building Integrated Molecular Diagnosis Platform

According to 36Kr.com, Jiaxing Aikenuo Biotechnology Co., Ltd. ("Aikenuo") has announced the completion of its Series A+ round, led by ZhenFund, with participation from existing shareholder Chuang Capital. Proceeds of this fianancing will be used to accelerate the clinical trials and registration of the automated molecular diagnostic platform and the first batch of test kits, as well as the research and development of new products. 

Previously, Aikenuo has raised its Series A financing led by CD Capital with participation from Nanchuang Capital.

Founded in July 2018 and headquartered in Zhejiang, Jiaxing City, Aikenuo is focused on the automation in molecular diagnostic testing, and development of automatic nucleic acid testing platform in the test lab and detection kits for clinical diagnosis of severe infection disease. The company has built production base of instruments and reagents in line with the GMP standard.

At present, Aikenuo has completed the development of an integrated molecular diagnosis platform based on fluorescence-based quantitative PCR technology and the panel for the detection of respiratory infection, which can provide a fully automated solution of "sample in, result out".

Chen Gaopeng, the vice President of ZhenFund, said that although the PCR technology, as a classical molecular diagnostic method, is facing the competition from NGS and other emerging technologies, it still has a great space for promotion in clinical application.

ZhenFund is a seed stage focused venture fund with over $1 billion under management since founded in 2011 by Bob Xu and Victor Wang, in collaboration with Sequoia Capital China. ZhenFund currently dominates China’s early stage venture capital scene, and is rapidly expanding its U.S. practice based in Palo Alto, CA. Its portfolio has over 750 high-growth companies.

Chuang Capital general partners are formed by NUS and NTU Chinese alumni, focusing on early stage venture investment in China, Hong Kong and Singapore with outstanding reward.